Effect of Cyclosporin A Treatment on the Production of Antibody in Insulin-dependent (Type I) Diabetic Patients

C. Boitard,* G. Feutren,* L. Castano,* M. Debray-Sachs,* R. Assen,* J. Hors,† and J. F. Bach*
*Institut National de la Santé et de la Recherche Médicale (INSERM) U 25 and Centre National de la Recherche Scientifique (CNRS) LA 122, Hôpital Necker, 75743 Paris, Cedex 15, France; †Service de Diabétologie, Hôpital Bichat, 75018 Paris, France; and ‡Hôpital Saint Louis, 75010 Paris, France

Abstract

Anti–islet cell and anti–insulin antibody production was studied over a 12-mo period in 82 recently diagnosed diabetics randomly receiving either cyclosporin or placebo. Cyclosporin had only minimal effects on the production of anti–islet cell antibodies whether directed to islet cytoplasmic (immunofluorescence) or membrane (cytotoxicity assay) antigens even in patients undergoing remission. These data suggest that these antibodies do not play a major role in the pathogenesis of the disease particularly since their (irregular) presence is not predictive of the clinical response to cyclosporin. Conversely, cyclosporin completely suppressed the synthesis of antibodies elicited by exogenous insulin irrespective of the insulin doses received, and decreased the autoantibody production against thyroid antigens, indicating that cyclosporin has variable effects on antibody production against various antigens.

Introduction

Cyclosporin A has recently been shown to increase the length and rate of remissions in insulin-dependent diabetes mellitus (IDDM) (1–3). This major therapeutic breakthrough, which confirms in man similar data previously reported in rodent models (BB rat, NOD mouse) (4–7), brings strong support for an autoimmune origin of IDDM. Such an autoimmune nature has already been strongly suggested by several lines of evidence. Anti–islet cell antibodies are commonly observed at an early stage of the disease (8, 9). In Caucasian populations, IDDM has been shown to associate with HLA-DR3 and/or DR4 antigens (10). Evidence that cell-mediated immunity has a major involvement in the lesion of the insulin-producing β-cell has been obtained from the high proportion of T lymphocytes observed in the cellular infiltrate within the islets of Langerhans in recent onset IDDM (11–13), from the capacity of purified T lymphocytes to inhibit insulin release by islet cells in vitro (14, 15), and from the potential role of interleukin 1 in islet β-cell destruction (16, 17). Transfer experiments clearly point to a predominant role of T lymphocytes in the NOD mouse model for spontaneous IDDM (18).

The problem remains however of the existence of a significant percentage of cyclosporin-resistant patients, and more generally of the mode of action of cyclosporin in this indication. We report here studies aimed at determining the immunological effects of cyclosporin A in IDDM patients that contribute to resolve these questions. Importantly, since data obtained in this investigation were compared with control data collected in a placebo group randomized with the cyclosporin A group, conclusions can be drawn despite the difficult problem of interference with the spontaneous evolution of immunological parameters in IDDM.

Methods

Patients. 82 patients in whom diagnosis of IDDM was established according to the World Health Organization criteria (19) were included in this study. These patients represent a large and unselected sample of the previously reported French randomized double-blind trial (3). 42 patients received 7.5 mg/kg body wt per d in a single oral dose of cyclosporin in olive oil (100 mg/ml) for 6–12 mo. 40 patients received placebo in the form of an equal volume (0.075 ml/kg body wt) of olive oil for 6–12 mo. The dosage of either cyclosporin A or placebo was increased to 10 mg/kg and 0.01 ml/kg body wt per d, respectively, at 3 mo, in case of persistent insulin requirement, to obtain the metabolic control defined below. The treatment was interrupted after 6 mo in case of failure. Failure was defined as insulin requirement above 0.25 U/kg body wt per d. Remission referred to decreased insulin requirement. Incomplete remission was defined as insulin requirement below 0.25 U/kg body wt per d to obtain a metabolic control defined by fasting glycemia below 7.8 mmol/liter, postprandial glycemia below 11.1 mmol/liter, and glycosylated hemoglobin Alc (HbAlc) below 7.5%. Normal value for HbAlc was 5.0±0.8% (2 SD). Complete remission was defined by fasting and postprandial glycemia, respectively, below 7.8 and 11.1 mmol/liter; and HbAlc below 7.5% in the absence of exogenous insulin or oral hypoglycemic agents.

Islet cell antibody (ICA) determination (immunofluorescence). ICA were determined by indirect immunofluorescence on frozen sections of a human group O pancreas using a fluoresceinated anti–human IgG serum (Wellcome Diagnostics, Dartford, England) as described by Bottazzo et al. (8). Complement-fixing ICA (CF-ICA) were determined on similar sections using a fluoresceinated anti–C3 serum (Dakopatts a/s, Glostrup, Denmark) (20). A technique using pretreatment of sera by aprotinin was performed as described by Elliott et al. (21) to determine sensitized ICA (S-ICA). Antibody titers were determined by serial log₂ dilutions. The precision and accuracy of ICA determination using the same pancreas as that used in this study was previously evaluated by the standard curve under the code number 4 as part of the First International Workshop on the standardization of cytoplasmic ICA (22). Intraassay variation was 95.6% when determining S-ICA titers of 22 samples studied blind twice. The specificity and sensitivity of ICA

Address correspondence and reprint requests to Dr. Boitard, INSERM U 25 and CNRS LA 122, Hôpital Necker, 75743 Paris, Cedex 15, France.

Received for publication 27 January 1987.

1. Abbreviations used in this paper: AlA, anti–insulin antibodies; CF-ICA, complement–fixing islet cell antibodies; HbA1c, hemoglobin Alc; ICA, islet cell antibodies; IDDM, insulin–dependent diabetes mellitus; S-ICA, sensitized ICA.

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/87/12/1607/06 $2.00 Volume 80, December 1987, 1607–1612
were considered positive. Pressed positive dilution anti-microsomal antibody (Wellcome, Basel, Switzerland). Commercial antibodies of maximal conditions were preincubation of complex release was evaluated. Anti-insulin antibodies were tested as 5 × 10^5 51Cr-labeled cells with 1 ml distilled water for 2 h. The specificity and sensitivit y of cytotoxic antibody determination were 90 and 46%, respectively, in the experimental conditions of the test.

HLA typing. All patients were typed for class II (DR1-DRw10) major histocompatibility complex antigens as previously described (24).

Anti–insulin antibodies (AIA). AIA were determined by immunoprecipitation of [125I]-labeled insulin (Novo, Copenhagen, Denmark) as previously described (25, 26) with slight modifications consisting of a preincubation of tested sera with charcoal. The sensitivity and specificity of the assay were 57 and 100%, respectively, in the experimental conditions used in this study.

Anti–thyroid antibodies. Anti–thyroglobulin and anti–microsomal antibodies were evaluated by a passive hemagglutination test using a commercial kit (Wellcome Diagnostics).

Cyclosporinemia. Cyclosporinemia was evaluated in total blood as a trough level 24 h after oral intake of the drug using a kit (Sandoz Ltd., Basel, Switzerland).

Expression of data. CF-ICA, ICA, S-ICA, anti–thyroglobulin and anti–microsomal antibody titers were expressed as the log2 value of the last positive dilution of tested sera. AIA were expressed as a percentage of ligand-bound radioactivity. Percentages above 1.9% (mean ± 2 SD) were considered positive. Cytotoxic antibodies to beta cells were expressed using the following index: tested serum (cycles per minute)/ maximal release (cycles per minute) × 100. Indexes > 33% (mean of control sera ± 2 SD) were considered positive. The statistical comparison of antibody titers observed in various groups was performed using the Student’s t test.

Results

ICA (indirect immunofluorescence). At inclusion in the trial S-ICA, ICA, and CF-ICA were detected in 47 (57.3%), 34 (41.4%), and 14 (17.1%), respectively, of all patients, which included 22 (55%), 16 (40%), and 7 (17.5%) of the placebo-treated patients, and 25 (59.5%), 20 (47.6%), and 7 (16.6%) of the cyclosporin A–treated patients. Initial titers of S-ICA, ICA, and CF-ICA at inclusion in the trial were not significantly different between placebo and cyclosporin A–treated patients (Fig. 1). No significant difference in ICA and S-ICA titers was observed between patients who ultimately showed or did not show remission in both the placebo and cyclosporin A group (Table I). Within complete remitters there was no statistically significant difference in antibody titers when considering the occurrence of a relapse (transient remission) as compared with the persistence of a stable remission during the follow-up period (data not shown). These data show that ICA positivity has no predictive value for the outcome of the disease in IDDM patients treated with cyclosporin A.

A slow decrease in S-ICA and ICA titers was observed in placebo and cyclosporin-treated patients over a 1-yr follow-up period, but this decrease was not statistically significant in both groups except when comparing initial and 12th mo ICA titers in cyclosporin-treated patients. The decline was slightly steeper in cyclosporin than in placebo-treated patients, but the difference was not statistically significant between both groups, even at 1 yr when it was the most clear-cut. There was also no significant difference when considering the percentage of patients positive for S-ICA and ICA at 12 mo between the cyclosporin group (56 and 25%, respectively) and the placebo group (50 and 22.7%, respectively).

Within the cyclosporin group, there was no significant difference in the evolution of the mean S-ICA and ICA titer between remitters (2.00 ± 0.67 SE, n = 11, and 0.45 ± 0.37 SE, n = 11, respectively, at 12 mo) and nonremitters (2.08 ± 0.71 SE, n = 12, and 0.46 ± 0.24 SE, n = 12, respectively, at 12 mo). Within the placebo group, the occurrence of a relapse in six remitters between the 6th and the 12th mo of follow-up was never accompanied by a reappearance or increase in S-ICA or CF-ICA titers, nor was this the case in the two patients who relapsed in the cyclosporin group. When individual data are considered in patients who stopped cyclosporin A treatment because of failure, a secondary reappearance of ICA or increase of titers was observed in 4 out of 13 patients by two dilutions (two patients) or three dilutions (two patients) within the six following months. This was never observed in the placebo group (18 patients).

Finally, the evolution of S-ICA and ICA titers did not appear to be clearly dependent on the mean cyclosporinemia level obtained during the first 6 mo of treatment (Table II).

Cytotoxic antibodies. At inclusion in the trial, cytotoxic antibodies to islet cells were observed in 14 (35%) placebo-treated patients and in 19 (45.2%) cyclosporin A–treated patients, again without correlation to ultimate occurrence of remission (data not shown). No close correlation was observed between S-ICA and cytotoxic antibodies. 12 patients had circulating cytotoxic antibodies in the absence of detectable S-ICA while 11 patients had S-ICA in the absence of detectable cytotoxic antibodies. No significant decrease in the mean cytotoxicity index was observed over one year of placebo treatment. A moderate decrease in the mean cytotoxicity index was noted in cyclosporin A–treated patients, but this decrease was not significant until 6 mo after starting treatment and again became nonsignificant at 12 mo. The mean cytotoxicity index values were never significantly different in cyclosporin and placebo groups over the 12-mo follow-up period (Fig. 2).
There was no significant difference in the evolution of cytotoxic antibodies depending on cyclosporinemia levels (data not shown).

AIA. AIA were detected in 22 (55%) placebo-treated patients and 21 (50%) cyclosporin A–treated patients at inclusion in the trial (which occurred 3–5 wk after initiation of insulin therapy). Follow up showed significantly lower levels of AIA in the cyclosporin A–treated group as compared with the placebo group at both 3 and 6 mo (Fig. 3). Cyclosporin A prevented the production of AIA in patients without detectable antibodies at the initiation of immunosuppressive therapy: the percentage of patients without detectable AIA after 6 mo of cyclosporin treatment (50%) was identical to that observed at entry in the trial. In the placebo group, the percentage of patients with detectable AIA rose from 55% at entry to 87.5% at 6 mo. Additionally, cyclosporin A strongly reduced preexisting AIA production when it was detectable at initiation of therapy. The level of AIA after 6 mo of cyclosporin treatment was lower than that at initiation of therapy in all patients but one. This later patient initially showed an increase in AIA levels from 2.2% of bound 125-I-iodine insulin to 15.1% at 3 mo of cyclosporin A therapy, then a decrease to 9.2% at 6 mo. Comparatively, in the placebo group, the percentage of bound 125-I-iodine insulin at 6 mo was significantly higher than that at entry into the trial in all patients but one, whose level was 1.8% at 6 mo, compared with 1.9% at initiation of therapy.

When considering only patients who did not stop insulin injections and were classified as failure at 6 months, the level of AIA was significantly lower at 3 and 6 mo in the cyclosporin A–treated group as compared with the placebo group (Fig. 4). A rebound effect on the production of AIA was observed when treatment with cyclosporin A was stopped at 6 mo. The level of AIA was higher at 9 and 12 mo in patients who stopped cyclosporin A treatment (failure) as compared with patients who stopped placebo at 6 mo, although this difference did not reach statistical significance (Fig. 4). It is important to stress that the mean daily insulin dose was not significantly different in both groups from the 7th to the 12th mo (33±3 SE and 31±3 SE U/d, respectively).

Finally, the occurrence of a relapse in patients in complete remission was never preceded by an increase in AIA (Table III). This precludes any predictive value of AIA in patients in complete remission.

**Anti-thyroid antibodies.** Eight patients in the cyclosporin A group had circulating anti–microsomal antibodies, compared to three in the placebo group. One of the eight patients in the cyclosporin A group also had anti–thyroglobulin antibodies while another patient had isolated anti–thyroglobulin antibodies. All three patients in the placebo group with anti–microsomal antibodies also had anti–thyroglobulin antibodies. The titer of anti–microsomal antibodies decreased signifi-

<table>
<thead>
<tr>
<th>Remission</th>
<th>No. patients</th>
<th>% Positive</th>
<th>Titer (log) (mean±SE)</th>
<th>% Positive</th>
<th>Titer (log) (mean±SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>25</td>
<td>56</td>
<td>3.76±0.60</td>
<td>40</td>
<td>1.4±0.41</td>
</tr>
<tr>
<td>Complete + partial</td>
<td>36</td>
<td>58.3</td>
<td>2.71±0.48</td>
<td>56</td>
<td>1.41±0.32</td>
</tr>
<tr>
<td>Failure</td>
<td>46</td>
<td>54.3</td>
<td>2.36±0.41</td>
<td>41</td>
<td>1.36±0.32</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>11</td>
<td>45.4</td>
<td>2.27±0.87</td>
<td>36.3</td>
<td>1.18±0.57</td>
</tr>
<tr>
<td>Complete + partial</td>
<td>13</td>
<td>46.1</td>
<td>2.15±0.76</td>
<td>45.4</td>
<td>1.08±0.49</td>
</tr>
<tr>
<td>Failure</td>
<td>26</td>
<td>57.7</td>
<td>2.81±0.58</td>
<td>42</td>
<td>1.08±0.37</td>
</tr>
<tr>
<td>Cyclosporin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>14</td>
<td>64.3</td>
<td>3.43±0.84</td>
<td>42.8</td>
<td>1.64±0.53</td>
</tr>
<tr>
<td>Complete + partial</td>
<td>23</td>
<td>68.2</td>
<td>3.09±0.57</td>
<td>64</td>
<td>1.57±0.40</td>
</tr>
<tr>
<td>Failure</td>
<td>20</td>
<td>50</td>
<td>2.20±0.56</td>
<td>40</td>
<td>0.85±0.28</td>
</tr>
</tbody>
</table>

There was no significant difference in the evolution of cytotoxic antibodies depending on cyclosporinemia levels (data not shown).

AIA. AIA were detected in 22 (55%) placebo-treated patients and 21 (50%) cyclosporin A–treated patients at inclusion in the trial (which occurred 3–5 wk after initiation of insulin therapy). Follow up showed significantly lower levels of AIA in the cyclosporin A–treated group as compared with the placebo group at both 3 and 6 mo (Fig. 3). Cyclosporin A prevented the production of AIA in patients without detectable antibodies at the initiation of immunosuppressive therapy: the percentage of patients without detectable AIA after 6 mo of cyclosporin treatment (50%) was identical to that observed at entry in the trial. In the placebo group, the percentage of patients with detectable AIA rose from 55% at entry to 87.5% at 6 mo. Additionally, cyclosporin A strongly reduced preexisting AIA production when it was detectable at initiation of therapy. The level of AIA after 6 mo of cyclosporin treatment was lower than that at initiation of therapy in all patients but one. This later patient initially showed an increase in AIA levels from 2.2% of bound 125-I-iodine insulin to 15.1% at 3 mo of cyclosporin A therapy, then a decrease to 9.2% at 6 mo. Comparatively, in the placebo group, the percentage of bound 125-I-iodine insulin at 6 mo was significantly higher than that at entry into the trial in all patients but one, whose level was 1.8% at 6 mo, compared with 1.9% at initiation of therapy.

When considering only patients who did not stop insulin injections and were classified as failure at 6 months, the level of AIA was significantly lower at 3 and 6 mo in the cyclosporin A–treated group as compared with the placebo group (Fig. 4). A rebound effect on the production of AIA was observed when treatment with cyclosporin A was stopped at 6 mo. The level of AIA was higher at 9 and 12 mo in patients who stopped cyclosporin A treatment (failure) as compared with patients who stopped placebo at 6 mo, although this difference did not reach statistical significance (Fig. 4). It is important to stress that the mean daily insulin dose was not significantly different in both groups from the 7th to the 12th mo (33±3 SE and 31±3 SE U/d, respectively).

Finally, the occurrence of a relapse in patients in complete remission was never preceded by an increase in AIA (Table III). This precludes any predictive value of AIA in patients in complete remission.

Anti-thyroid antibodies. Eight patients in the cyclosporin A group had circulating anti–microsomal antibodies, compared to three in the placebo group. One of the eight patients in the cyclosporin A group also had anti–thyroglobulin antibodies while another patient had isolated anti–thyroglobulin antibodies. All three patients in the placebo group with anti–microsomal antibodies also had anti–thyroglobulin antibodies. The titer of anti–microsomal antibodies decreased signifi-

---

**Table II. Relationship between the Evolution of Cytoplasmic ICA Titer and the Mean Cyclosporinemia Level over the First 6 mo of Treatment**

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Cyclosporinemia (mean±SE) ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable S-ICA titer</td>
<td>18</td>
</tr>
<tr>
<td>Decreasing S-ICA titer</td>
<td>7</td>
</tr>
<tr>
<td>Stable ICA titer</td>
<td>8</td>
</tr>
<tr>
<td>Decreasing ICA titer</td>
<td>12</td>
</tr>
</tbody>
</table>

---

**Figure 2. Cytotoxic antibodies in placebo and cyclosporin A–treated patients over a 12-mo follow-up period. The mean (mean±SE) cytotoxicity index in placebo (open circles) and cyclosporin A (CyA) (closed circles)–treated patients is indicated over the 12 mo follow-up period. Numbers in parentheses indicate the number of tested sera. Statistical evaluation is as in Fig. 1. There is no significant difference at 1, 3, and 12 mo of treatment within each group.**
cantly after 6 mo of treatment in the cyclosporin A group as opposed to the placebo group (Fig. 5). Although the number of patients with anti-thyroglobulin antibodies is small in both groups, it is worth noting that anti-thyroglobulin antibodies disappeared in one patient, decreased by five log₂ dilutions in the other patient under cyclosporin A, and remained unmodified or increased by one and two dilutions in the three patients receiving placebo when comparing the 6-mo value to that detected at entry into the trial. Out of the eight patients with detectable anti-microsomal antibodies, six also had cytoplasmic ICA. In these six positive patients, the titer of S-ICA remained unmodified at six months, while anti-microsomal antibodies became undetectable in one, decreased by two dilutions in three, by four dilutions in one, and remained unmodified in one patient.

HLA-DR phenotype. 88% of treated patients were either HLA-DR3 or DR4. 30% of patients were both DR3 and DR4. No significant difference was detected in the titer of ICA, cytotoxic antibodies to islet cells, or AIA in patients of the various DR phenotypes, with the exception of non-DR3, non-DR4 patients, who showed a lower (statistically nonsignificant) incidence of cytoplasmic and cytotoxic anti-islet antibody (Table IV). In addition, since the incidence of remissions was not different in DR3-X, DR4-X, DR3-4, and non-DR3, non-DR4 patients, this preliminary analysis provided no clear evidence that the HLA-DR phenotype allowed any prediction in terms of remission or relapse in clinical remitters.

Discussion

ICA were detected in 42% of all patients before starting cyclosporin A and placebo treatment using the conventional method described by Bottazzo et al. (8, 20). With the complement fixation method positivity was even lower (17%). These figures are below the percentages reported in other series. We have not found such a discrepancy, however, in other groups of diabetic patients, including children or sera studied at the standardization workshop (22). We detected ICA in 58% of all patients using a sensitized method previously reported by Elliott et al. (21). Figures for cytotoxic antibodies and anti-thyroid antibodies are consistent with those previously reported in other series (23, 27–29). Our results are in accordance with data from the Canadian trial, which indicated that ICA detection is of no value in predicting the therapeutic response to cyclosporin A in IDDM (30). Neither ICA or IAA can be considered as good predictors of relapse in IDDM patients in clinical remission whether or not they are receiving cyclosporin A. Moreover, we observed no correlation between the disappearance of ICA and the induction of clinical remissions. In contrast with data reported from the Canadian open trial (30), we did not find an inverse correlation between the mean ICA titer and the remission rate. Such a discrepancy may be due to differences in the definition of remission criteria.

It is clear from our study that cyclosporin A has only a moderate effect on the titers of both ICA and anti-islet cell cytotoxic antibodies. This finding is consistent with previous data from the Canadian cyclosporin A open trial, which indicated an only moderate effect of cyclosporin A therapy on ICA titers in IDDM (30). The absence of correlation between ICA titers and the induction of remission, and the delayed reduction in ICA titer as compared with the onset of remission, suggest that ICA are secondary to rather than responsible for the islet β-cell destruction. In fact, the absence of an obvious effect of cyclosporin A on anti-islet antibody production contrasted with the clear-cut effect observed in the same patients with 6 mo of cyclosporin therapy (concomitantly with complete remissions) on T cell capacity to inhibit insulin release in vitro (2).

The minor and late reduction of ICA titers in the cyclosporin A group after a 12-mo treatment follow-up may indi-
c co can either that ICA production is under T lymphocyte control or less likely that ICA production is dependent on cyclosporin A-sensitive B lymphocytes. These hypotheses are interesting in the light of our knowledge of the mechanism of immuno-suppressive activity of cyclosporin A. Cyclosporin A mainly inhibits helper T cells by suppressing interleukin 2 production (31–33), or by suppressing the expression or responsiveness of interleukin 2 receptors (34, 35), and as a consequence depresses both cell-mediated immune responses (36) and T-dependent antibody production (37). Whether cyclosporin A has a direct effect on B lymphocytes remains controversial (38–40). Cyclosporin A inhibits some humoral immune responses when given at the time of the antigenic challenge. Conversely, cyclosporin A poorly affects established antibody production by B lymphocytes primed before cyclosporin A administration, as shown by studies of the response to non-self antigens (41). In spontaneous or induced autoimmune diseases in animals, cyclosporin A treatment inhibits autoantibody production when given before rather than after the appearance of autoantibodies, as shown in thyroiditis (42, 43) and experimental myasthenia gravis (44). Conversely, cyclosporin shows little or no effect on autoantibody production in experimental uveitis in the rat (45) and in spontaneous thyroiditis in the obese strain chicken (46). The only exception is in lupus mice, where an established anti-DNA autoantibody production has been shown to be inhibited by cyclosporin A (47).

To date, very little is known on the effect of cyclosporin A on autoantibody production in human autoimmune diseases. Disappearance of anti–skin antibodies has been reported in patients suffering from bullous pemphigoid (48). By contrast, no inhibition of anti–double-stranded and antinuclear DNA antibodies has been reported in systemic lupus erythematosus over a 6-mo follow-up period (49). Finally, it is interesting to note that in the responses to exogenous keyhole limpet hemocyanin and tetanus toxoid, cyclosporin A–treated patients with chronic uveitis showed a significant inhibition of delayed-type cutaneous hypersensitivity reactions but no significant reduction of antibody production (50). Conversely, a moderate inhibition of the humoral response to influenza vaccination has been reported in cyclosporin A–treated renal transplant patients (51).

Our data indicate a clear-cut difference in the action of cyclosporin A on established anti–islet autoantibody production and the immune response to exogenous insulin. Since the mean duration of insulin therapy was 22 d before starting cyclosporin A treatment, we assume that AIA were not autoantibodies as may be found in diabetic patients before initiation of insulin therapy, but were antibodies directed at exogenous insulin. Importantly, the decreased level of AIA in patients treated with cyclosporin A was observed independently of the induction of remission. That established AIA production was strongly inhibited by cyclosporin A treatment is discordant with the differential action of cyclosporin A on antibody production discussed above, depending on its introduction before or after the antigenic challenge. When considering anti–thyroid autoantibody titers, it appears that cyclosporin A also inhibited established anti–thyroid antibody production at variance with the absence of obvious effect observed on anti–islet antibody production. This difference may be interpreted as indicating either a different level of autoimmunization against the two organs or a higher involvement of T cells in thyroiditis as compared with IDDM. The latter hypothesis is unlikely, since anti–islet cell autoantibodies are of the IgG (presumably thymus dependent) isotype.

Acknowledgments

We thank H. Blondel, H. Cohen, and M. Lecuyer for their excellent technical assistance. We are deeply indebted to Dr. B. Charbonnel, Dr. D. Du Rostu, Dr. Ph. Passa, Dr. M. Pehuet, Dr. G. Tchobroutsky, and Dr. P. Vexiau, who were involved in the Cyclosporin Diabetes French (CDF) study as participating clinicians.

Dr. Castano was supported by INSERM U188, Hospital Saint Vincent de Paul. This work was supported by INSERM, CNRS, and Sandoz Laboratory, Rueil Malmaison, France, as part of the CDF study.

References


Table IV. Percentages of Patients with Anti-ICA According to HLA-DR Phenotypes

<table>
<thead>
<tr>
<th>HLA marker</th>
<th>No. patients</th>
<th>S-ICA</th>
<th>CF-ICA</th>
<th>Cytotoxic antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR3-X</td>
<td>51</td>
<td>68.6</td>
<td>17.6</td>
<td>43</td>
</tr>
<tr>
<td>DR4-X</td>
<td>43</td>
<td>62.7</td>
<td>16.2</td>
<td>42</td>
</tr>
<tr>
<td>DR3/4</td>
<td>24</td>
<td>70.8</td>
<td>12.5</td>
<td>50</td>
</tr>
<tr>
<td>DRX</td>
<td>7</td>
<td>28.5</td>
<td>0</td>
<td>28.5</td>
</tr>
</tbody>
</table>

Effect of Cyclosporin A on Antibody Production in Type 1 Diabetic Patients


